Physiomics PLCLSE: PYC

Physiomics: Result of AGM, Issue of Equity & TVR

· Issued by Physiomics PLC via RNS

Summary by 6ix AI

Physiomics, which helps biotech and pharma companies with modelling, simulation and data analysis in drug development, said all resolutions at its Annual General Meeting held on 5 November 2026 in London were passed. Following the meeting, it will issue 14,000,000 new ordinary shares to three directors in place of part of their cash pay.

Key details

  • Chairman Nick Tulloch will be issued 4,000,000 new shares, representing remuneration of £20,000. Executive Director Mike Whitlow and Finance Director Ian Bagnall will be issued 5,000,000 new shares each, representing remuneration of £25,000.
  • The new shares are priced at 0.50 pence each, the closing price on 28 April 2026, the day before the directors joined the board. The directors agreed to take shares instead of part of their cash pay, as first announced on 30 June 2026.
  • Physiomics had 453,208,718 shares in issue at 6:30 p.m. (UK) on 4 November 2026 and holds no shares in treasury. After the new shares are admitted to trading, total voting rights will be 467,208,718, a figure shareholders can use to work out whether they must disclose their holding under the Financial Conduct Authority's rules.

What’s still pending

  • An application has been made for the 14,000,000 new shares to trade on AIM, the London stock market for smaller companies; trading is expected to start on or around 8:00 a.m. on 11 November 2026.

6ix AI wrote this summary from the release below and checked it against the release.

Physiomics PLC
05 November 2026

Physiomics | Physiomics - Model Informed Drug Development - Pharmacometrics, Quantitative System Pharmacology and Biostatistics Consulting
5 November 2026

Physiomics plc

("Physiomics" or the "Company")

Result of AGM

Issue of Equity, TVR, and Directors' Dealing

The Annual General Meeting of Physiomics was held today at 10.30 a.m. (GMT) at Strand Hanson, 26 Mount Row, Mayfair, London, W1K 3SQ. The Company is pleased to confirm that all resolutions put to shareholders were duly passed.

Full details of the poll results are set out below:

Resolution

For

Against

Discretion to Chairman

Withheld

Total

01

34,189,515

334,719

Nil

2,383

34,526,617

02

31,959,123

386,078

Nil

2,181,416

34,526,617

03

33,335,879

334,719

Nil

856,019

34,526,617

04

33,335,879

334,719

Nil

856,019

34,526,617

05

33,335,879

334,719

Nil

856,019

34,526,617

06

33,327,858

334,719

Nil

864,040

34,526,617

07

33,328,453

334,719

Nil

863,445

34,526,617

08

34,140,207

384,027

Nil

2,383

34,526,617

09

33,335,879

334,719

Nil

856,019

34,526,617

10

32,019,098

334,719

Nil

2,172,800

34,526,617

The number of shares in issue at 6:30 p.m. (UK) on 4 November 2026 was 453,208,718. The Company does not hold any shares in treasury.

Issue of Equity

As announced on 30 June 2026, the board of directors of Physiomics (the "Board" or the "Directors") agreed to receive new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in lieu of part of their cash remuneration.  Following the AGM, Nick Tulloch, Chairman, will be issued 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will be issued 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board.

Admission and Total Voting Rights

Application has been made for 14,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 8:00 a.m. on 11 November 2026. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the Company's enlarged share capital will comprise 467,208,718 Ordinary Shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 467,208,718. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Mike Whitlow

Email:  [email protected]

Strand Hanson Ltd (NOMAD and Broker)

James Dance & James Bellman

Tel:  +44 (0) 20 7409 3494

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Nick Tulloch

Non-Executive Chairman

Mike Whitlow

Executive Director

Ian Bagnall

Finance Director and Company Secretary

2.

Reason for the Notification

a)

Position/status

See 1a) above

b)

Initial notification/Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics Plc

b)

LEI

213800A71DSZ6ABMTQ91

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 0.4p each in Physiomics Plc

Identification code

ISIN: GB00BDR6W943

b)

Nature of the transaction

Remuneration Shares

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Nick Tulloch

£0.005

4,000,000

Mike Whitlow

£0.005

5,000,000

Ian Bagnall

£0.005

5,000,000

d)

Aggregated information:

-  Aggregated volume

14,000,000

-  Price

£0.005

e)

Date of the transaction

5 November 2026

f)

Place of the transaction

Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Physiomics PLC on 6ix

Story so far

Earlier from Physiomics

All Physiomics news releases